Background Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous coronary intervention (PCI). However, the greatest antiischaemic benefit of potent antiplatelet drugs over the less potent clopidogrel occurs early, while most excess bleeding events arise during chronic treatment. Hence, a stage-adapted treatment with potent platelet inhibition in the acute phase and de-escalation to clopidogrel in the maintenance phase could be an alternative approach. We aimed to investigate the safety and efficacy of early de-escalation of antiplatelet treatment from prasugrel to clopidogrel guided by platelet function testing (PFT).
Introduction
Activation of blood platelets plays a key part both in the initiation and during the early phase of an acute coronary syndrome. Consequently, clinical outcomes of patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) have been significantly im proved and ischaemic risk has been reduced with the use of potent P2Y 12 receptor inhibitors like prasugrel or ticagrelor, albeit at the expense of an increased bleeding risk. [1] [2] [3] [4] Current acute coronary syndrome guidelines recom mend potent P2Y 12 receptor inhibitors for 1 year in patients with acute coronary syndrome managed by PCI. 5 However, the greatest benefits of these potent drugs are seen early, when the risk of ischaemic complications is highest, while most haemorrhagic events with potent platelet inhibitors arise during chronic treatment. 3, 4 This rationale has fuelled interest in strategies of stepwise deescalation 6 using potent P2Y 12 inhibitors only in the early phase of treatment, and using the less potent clopidogrel during the chronic treatment course. However, to date, the evidence sup porting safety and efficacy and thereby justifying de escalation is limited and the few available data from smaller studies are conflicting. 7, 8 Despite the absence of unequivocal evidence, deescalation of antiplatelet therapy after acute coronary syndrome is quite common in clinical practice [8] [9] [10] [11] and about 15-28% of patients with acute coronary syndrome 9 are switched from potent to less potent treatment after discharge. This occurs for several reasons, including adverse bleeding events or non bleeding events, a perceived high bleeding risk, and economic issues favouring offpatent clopidogrel. 1, 9, 11 Nevertheless, any deescalation of antiplatelet therapy from a potent P2Y 12 inhibitor to the less potent clopidogrel should account for large response variability of the latter 12 and the consequential issue of high ontreatment platelet reactivity (HPR), which exists in a substantial proportion of patients with acute coronary syndrome. [13] [14] [15] Patients with HPR exhibit an increased risk for recurrent ischaemic events, including myocardial infarction and stent thrombosis. [13] [14] [15] Hence, platelet function testing (PFT) could serve to make deescalation safer by identi fying patients with HPR on clopidogrel, who might be exposed to an increased risk of thrombotic events due to insufficient P2Y 12 inhibition and who should therefore continue potent P2Y 12 inhibitors like prasugrel. Thus, we aimed to investigate the safety and efficacy of a PFTguided early deescalation of antiplatelet treatment compared with standard prasugrel therapy in patients with acute coronary syndrome undergoing PCI.
Methods

Study design and patients
The Testing Responsiveness To Platelet Inhibition On Chronic Antiplatelet Treatment For Acute Coronary Syn dromes (TROPICALACS) trial was an investigator initiated, randomised, parallelgroup, openlabel,
Research in context
Evidence before this study International guidelines recommend potent platelet inhibition with prasugrel or ticagrelor in the first year after an acute coronary syndrome. Despite these recommendations, a regimen implying early de-escalation from potent antiplatelet agents to the less potent and off-patent clopidogrel is appealing both from a conceptual and economic perspective. We searched MEDLINE on July 1, 2017, for articles in English with the search terms "antiplatelet treatment de-escalation", "switching antiplatelet therapy", and "acute coronary syndrome guidelines", and found only a few studies with a focus on clinical outcomes (TRANSLATE-ACS, SCOPE registry, TOPIC trial). Data from the TRANSLATE-ACS registry showed that de-escalation is common clinical practice with up to 28% of patients with acute coronary syndrome switching from potent platelet inhibition down to clopidogrel within the first year post discharge on their own or their physician's initiative. The reasons for de-escalation most predominantly include adverse events and issues with reimbursement or availability of potent platelet inhibitors. However, to date, evidence supporting safety and efficacy and thereby justifying de-escalation is lacking and even conflicting. While data from a single registry (SCOPE) pointed towards potential hazards of de-escalating treatment after acute coronary syndrome, a smaller single-centre randomised trial (TOPIC) favoured uniform de-escalation of treatment in eventfree patients with acute coronary syndrome at 1 month after percutaneous coronary intervention, mainly driven by a reduction of Bleeding Academic Research Consortium (BARC) grade 2 or higher bleeding in patients receiving de-escalated antiplatelet treatment.
Added value of this study
To the best of our knowledge, TROPICAL-ACS is the first randomised trial to investigate a strategy of early and guided de-escalation of P2Y 12 inhibition in patients with acute coronary syndrome. The trial population represents a high-risk cohort of biomarker-positive patients with acute coronary syndrome including more than 1400 patients with ST-elevation myocardial infarction. De-escalation guided by platelet function testing (PFT) ensured sufficient platelet inhibition in all patients with acute coronary syndrome in the experimental arm, with about 60% of patients continuing on clopidogrel treatment and 40% of patients requiring escalation back to prasugrel. By showing non-inferiority of PFT-guided de-escalation compared with a standard of potent platelet inhibition for 12 months, our trial provides important evidence justifying tailored de-escalation as an alternative strategy in patients with acute coronary syndrome after coronary stenting. Study results are applicable to all scenarios of de-escalation, regardless of whether the need to de-escalate arises from clinical or economic issues. PFT results can help to justify de-escalation in clopidogrel responders, while they might also help to overcome budgetary issues for patients that would require escalation back to prasugrel.
Implications of all the available evidence
Based on all the available evidence, uniform and potent platelet inhibition in patients with acute coronary syndrome probably remains standard of care, because TROPICAL-ACS did not show superiority of de-escalation. Notwithstanding, alternative treatment concepts are desired for a significant proportion of patients in clinical practice. Our trial now supports the safety and efficacy of an early and guided de-escalation of platelet inhibition in patients with acute coronary syndrome as an alternative strategy that can be followed whenever necessary for medical or socioeconomic reasons. The regimen of guided treatment seems also practical beyond the framework of a randomised controlled trial, because patients in many countries worldwide typically have planned outpatient visits within the first weeks after an acute coronary syndrome.
assessorblinded, multicentre trial that was done at 33 European sites (two in Austria, 20 in Germany, seven in Hungary, and four in Poland) and had an academic sponsor (Klinikum der Universität München). Patients were eligible if they had biomarkerpositive acute coronary syndrome with a successful PCI (defined as a postPCI diameter stenosis <20% and thrombolysis in myocardial infarction [TIMI] flow ≥2), and planned treatment of prasugrel for 12 months after the procedure. The appendix (p 2) lists all inclusion and exclusion criteria; the study protocol with further details has been published previously. 16 Patients provided written informed consent. An inde pendent data safety monitoring board (DSMB) over saw the trial and had full access to unblinded data. Study monitoring for all patients was done by an ex ternal service provider (Münchner Studienzentrum, MSZ, Munich, Germany). The institutional ethics com mittee of each participating site, as well as the competent national agencies approved the trial. The study was conducted in accordance with the principles of the Declaration of Helsinki.
Randomisation and masking
Using an internetbased randomisation procedure with a computergenerated block randomisation with strati fication across study sites, patients with acute coronary syndrome were randomly assigned before planned discharge in a 1:1 fashion to the two study groups of either PFTguided deescalation or control group. Patients were considered enrolled in the study and eligible for the final intentiontotreat analysis at the time of randomisation. Figure 1 summarises the study flow of the TROPICALACS study. Patients in the control group received a standard care of 12 month prasugrel treatment at a dose of 10 mg or 5 mg according to the label and the current guideline recommendations. 5, 17 Patients in the deescalation group received a postdischarge treatment, consisting of 1 week prasugrel treatment (10 mg or 5 mg per day) followed by 1 week of clopidogrel treatment (75 mg per day) and a platelet function measurement (on clopidogrel) 2 weeks after hospital discharge (PFTguided deescalation group). Based on PFT results in the guided deescalation group, patients were either switched back to prasugrel, when a status of HPR with insufficient platelet inhibition was detected, whereas patients with sufficient platelet inhibition (no HPR) continued with clopidogrel.
Study grouprelated treatment was planned to start on the day after discharge and study drugs for the first 14 days post discharge were packed and provided by the pharmacy department of the Klinikum der Universität München (Munich, Germany). We deemed this necessary to guarantee an exact intake of tablets during a time frame covering the switch of treatment in the guided de escalation group. For both groups, three extra tablets (provisional medication) were included in the box for week 2 to ensure flexibility regarding the timing of the first followup visit out to day 17. Treatment after day 14 post discharge until 12 months was planned according to the assigned randomisation and HPR status in the guided deescalation group and was prescribed by the patient's primary care physician in both study groups. Further details on randomisation procedures and study drugs were published previously.
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Procedures 2 weeks after discharge from the primary care hospital, where the index PCI was done, all patients had an outpatient visit. In addition, patients were contacted by phone call at 30 days, 6 months, and 12 months after randomisation. These calls were made to explore study endpoints and adverse events and to assess adherence to the assigned antiplatelet therapy using a studyspecific designed standardised questionnaire. In case of a suspected clinical event all source data were collected to allow for precise event adjudication by the event adjudication committee.
For the onsite followup visit, participants from both study groups underwent planned and prescheduled blood sampling for PFT under steadystate conditions. The Multiplate analyser (Roche Diagnostics, Rotkreuz, Switzerland) was used for testing. Details of this method and its predictive value have been published prev iously. 13, 14, 16 A status of HPR was defined based on the results of previous studies and the consensus documents of the Working Group on HPR as an adenosine diphosphate test aggregation value of 46 units or higher on the Multiplate analyser. 13, 14 In the control group, testing was done only for obser vational purposes and results did not affect drug selection or dosing. In the guided de escalation group, testing results determined the further course of treatment: patients with HPR were immediately switched back to prasugrel, while those without HPR continued on clopi dogrel (figure 1).
Outcomes
The primary endpoint was a combined ischaemic and bleeding endpoint (net clinical benefit), which was the composite of death from cardiovascular causes (all deaths were assumed cardiovascular in nature unless a non cardiovascular cause could be clearly provided), myo cardial infarction (defined according to the 3rd universal definition of myocardial infarction 18 ), stroke, and bleeding grade 2 or higher defined according to Bleeding Academic Research Consortium (BARC) criteria 19 at 12 months after randomisation. The key secondary endpoint was defined as BARC class 2 or higher bleeding events at 12 months. Further secondary endpoints included the ischaemic components (com bined and singular) of the primary endpoint (cardio vascular death, myocardial infarction, and stroke), stent thrombosis defined according to Academic Research Consortium (ARC) criteria, 20 the incidence of death from any cause, and urgent ischaemia driven revascularisation at 12 months. With respect to bleeding events, all reported bleedings were assessed and reported according to BARC classification (BARC types 1-5). An independent event adjudication committee masked to treatment assignment adjudicated all sus pected clinical events.
Statistical analysis
The study was designed to show noninferiority for the guided deescalation group versus the control group regarding the primary composite endpoint. Considering the results of a landmark analysis from the TRITON TIMI 38 trial, 3 based on the incidence of early versus late major bleeding events 3 and based on the incidence of BARC 2 or higher bleeding complications in a PCI cohort, 21 the incidence of the primary endpoint of this study was assumed to be 10·5% in the control group. A noninferiority margin of 30% was estimated, which is in accordance with noninferiority margins used in contem porary trials of antithrombotic treatment in cardiovascular diseases. 22, 23 Sample size calculations (nQuery Advisory, Statistical Solutions, Farmer's Cross, Cork, Ireland) were done based on a onesided type 1 error of 5% and a power of 80%. For the primary endpoint assumptions, 1172 patients in each group were needed. Assuming an incidence of BARC 2 or higher bleeding in the control group of 4·9% and an expected reduction of BARC 2 or higher bleeding by 45% in the deescalation group, 1179 patients per group would be required to show superiority (based on twosided type 1 error of 5% and a power of 80% for the key secondary endpoint (BARC 2 or higher bleeding). To compensate for losses to followup and to be powered for the primary and secondary endpoint assessment the enrolment of a total of 2600 patients (1300 patients per group) was planned. All analyses were done on an intentiontotreat basis. In addition, perprotocol analyses were done. Differences in endpoints were analysed in Coxregression models for survival analysis. In all cases of the use of the Cox proportional hazards model, the proportional hazards assumption was met. KaplanMeier plots were generated to visualise the risk of outcome events in both groups. Binary and other categorical variables were compared using Fisher's exact test and χ² test, respectively, for continuous data twosided unpaired Wilcoxon test or Student's t test were used as appropriate. Data were analysed with R version 3.3.0.
Role of the funding source
The funders of this study had no role in study design, collection of data and data analysis, or writing of the manuscript. DS and SM had full access to the data and take full responsibility for the decision to submit for publication.
This study is registered with ClinicalTrials.gov, number NCT01959451, and EudraCT, 201300163622.
Figure 1: Study design and groups
The figure shows the control group and the experimental group with guided de-escalation of antiplatelet treatment. Patients were randomly assigned (1:1) after PCI and directly before planned discharge from hospital. On-treatment platelet reactivity was measured in both study groups. In the control group, on-prasugrel testing results had no effect on further treatment, which was prasugrel for all patients. Based on the testing results in the guided de-escalation group (on clopi dogrel treatment), the further treatment was determined at day 14 post discharge. Protocol-mandated treatment required clopidogrel in no-HPR patients and a switch back to prasugrel in HPR patients. PCI=percutaneous coronary intervention. HPR=high on-treatment platelet reactivity. R*=randomisation. DAPT=dual antiplatelet therapy. 
Results
Between Dec 2, 2013, and May 20, 2016, 2610 eligible patients with acute coronary syndrome were randomly assigned at 33 European PCI sites (figure 2). These patients constitute the intentiontotreat population, in which 1306 patients were randomly assigned to the control group and 1304 patients to the guided de escalation group. Mean age of patients was 59 years (SD 10) and 558 (21%) were women. 1453 (56%) patients presented with STelevation myocardial infarction (STEMI). Table 1 summarises the baseline characteristics  of the study cohort and table 2 provides an overview of procedural characteristics of the index PCI. For the prescheduled followup visit at 2 weeks after hospital discharge the followup rate was 98% in the guided deescalation group and 99% in the control group. In the guided deescalation group, a status of HPR was noted in 511 patients (39% of the intentiontotreat population). In line with the protocol, 506 (99%) of the 511 patients were switched back from clopidogrel to prasugrel, while only five patients with HPR continued clopidogrel based on an individual decision of the treating physician at the followup visit. In the control group, a status of HPR was found in 188 patients (14% of the intentiontotreat population). Adherence to the assigned P2Y 12 inhibitor therapy was repeatedly assessed throughout the study in all patients. During the study period of 12 months, adherence to the protocolmandated treatment was high with a rate of 94·2% in the control group and 94·4% in the guided deescalation group. Use of lowdose (5 mg per day) instead of standard dose prasugrel (10 mg per day) for study drug treatment was low (4·0% in guided deescalation group vs 4·2% in control group) and did not differ between the study groups (p=0·88). During the 1year study period, 43 patients (2%) withdrew consent and 110 (4%) were lost to followup (figure 2). figure 3A) . The ischaemic components of the primary endpoint (cardiovascular death, myocardial infarction, and stroke) occurred in 32 patients (3%) in the guided deescalation group and in 42 patients (3%) in the control group (HR 0·77 [95% CI 0·48-1·21]; p=0·25; figure 3C ), indicating that early deescalation did not result in an increased risk of cardiovascular death, myocardial infarction, or stroke (p noninferiority =0·0115). Table 3 sum marises relevant outcome data for all individual components of the combined ischaemic endpoint. No significant differences were observed for any of the ischaemic components of the primary endpoint (p≥0·22) as well as for the rate of urgent revascularisation (p=0·13). All cause mortality at 1 year was 1% (12 events) in the control group versus 1% (11 events) in the guided de escalation group (p=0·85). The cumulative incidence of definite stent thrombosis was low with two events (<1%) in the guided deescalation group versus three events (<1%) in the control group (HR 0·67 [95% CI 0·11-4·03]; p=0·66).
The incidence of the key secondary endpoint of BARC 2 or higher bleedings was 5% (64 events) in the guided de escalation group versus 6% (79 events) in the control group (HR 0·82 [95% CI 0·59-1·13]; p=0·23; figure 3B). The cumulative incidence of all bleeding events (BARC class 1 to 5) was 9% (114 events) in the guided de escalation group versus 11% (137 events) in the control group (HR 0·83 [95% CI 0·65-1·06]; p=0·14; figure 3D). 
Discussion
Deescalation of antiplatelet treatment after an acute coronary syndrome is conceptually appealing and frequently practised in realworld scenarios. 6, [8] [9] [10] [11] [24] [25] [26] Nevertheless, there is little evidence until now to justify switching regimens. TROPICALACS is currently the only trial investigating a concept of guided deescalation of P2Y 12 inhibition in an allcomers cohort of patients with acute coronary syndrome. Key findings from this study are that a stageadapted antiplatelet treatment strategy with initial potent platelet inhibition using prasugrel, followed by guided dual antiplatelet treatment (DAPT) deescalation to clopidogrel proved to be feasible and noninferior to conventional 12month prasugrel therapy. In particular, the rate and distribution of ischaemic events were not increased with guided DAPT deescalation. Hence, this study identifies guided DAPT deescalation as an alternative strategy in patients with acute coronary syndrome that are deemed unsuitable for maintained potent platelet inhibition for whatever medical or socioeconomic reasons. 9 Several further observations are worth mentioning. First, by contrast with previous studies investigating concepts of uniform deescalation, 7, 8 we used individ ualised PFTguided deescalation in this study. Landmark data 3,4 from PLATO and TRITONTIMI 38 trials showed that even though protection from recurrent ischaemia with potent agents was most prominent during the acute phase, it persisted throughout chronic treatment out to 12 months after an acute coronary syndrome. Hence, PFT guidance of deescalation was applied to guarantee sufficient platelet inhibition in all patients with acute coronary syndrome during their chronic course of treatment. Second, adherence to perprotocol DAPT was higher than in many other recent trials of acute coronary syndrome 1, 7, 10 and ischaemic risk was low in both study groups. These observations could be related to the fact that drug treatment was monitored in all patients enrolled into our trial, which potentially had beneficial effects on patient compliance. Third, high drug adherence and followup rates within this study proved the feasibility of guided deescalation as early as 1 week after patient's discharge. DAPT deescalation seems clinically most relevant when applied early, considering that adverse events, including sideeffects and bleeds, occur over time during maintenance therapy. Nevertheless, it seems reasonable to extrapolate from this study that de escalation would also be feasible and safe at later stages during chronic antiplatelet treatment. Further on, the rate of ischaemic events was lower in this study than in previous trials, including TRITONTIMI 38 and PLATO. 1, 2 It must be emphasised that randomisation in our trial was done before discharge and hence several days after PCI. Thus, early and periprocedural events that dominated the overall event rates of previous studies 1, 2 were not included in our trial. This together with the increased safety of contemporary PCI with a high rate of radial access and use of latest generation drugeluting stents (eg, everolimuseluting or zotarolimuseluting stents) are likely explanations for the lower risk of ischaemic events in our trial. Previous trials addressing concepts of deescalation of antiplatelet treatment are limited and have yielded somewhat conflicting findings. Observational data from the SCOPE 8 registry enrolling 1363 patients with acute coronary syndrome showed that deescalation from potent antiplatelet inhibitors to clopidogrel was independently associated with adverse events during chronic DAPT. By contrast, the recent TOPIC trial 7 reported that a switch over from ticagrelor or prasugrel to clopidogrel 1 month after PCI for acute coronary syndrome reduced bleed ing complications. However, TOPIC differs essentially from this study in various aspects: first, primary end point selection (composite of cardiovascular death, un planned hospital admission leading to urgent coronary revascularisation, stroke, and bleeding episodes as defined by the BARC type ≥2) allowing for a smaller sample size to show superiority (645 patients in TOPIC vs 2610 patients in TROPICALACS); second, the monocentric study design in TOPIC; third, a moderate adherence (75%) to treatment in the control group of TOPIC; fourth, TOPIC did not specifically report important ischaemic endpoints like myocardial infarction or stent thrombosis, limiting the conclusions that can be made regarding safety aspects of deescalation; and most importantly, fifth, TOPIC used uniform deescalation switching all patients in the de escalation arm from an established potent P2Y 12 inhibitor to the less potent clopidogrel. By contrast, our study accounts for the substantial response variability of clopidogrel 12, 14, 15 and considers the persistent antiischaemic potential of sufficient platelet inhibition seen during the chronic treatment phase.
1,2 This is achieved by imple mentation of drugresponse testing precluding de escalation in patients with HPR, carrying a higher risk of thrombotic events in a background of insufficient P2Y 12 inhibitor therapy. 14, 15 Findings from this study show that PFTtailored deescalation is safe, because none of the ischaemic endpoints-alone or in combination-tended to be higher in the guided deescalation group than in the control group. We also did not observe any clustering of thrombotic events during the early phase of treatment after discharge, where antiplatelet drugs were switched per protocol in the guided deescalation group.
Besides recurrent ischaemia, bleeding complications are among the most frequent adverse events after PCI, both during the acute and even more so during the maintenance phase of treatment. 3, 4 We observed numerically more events across all BARC classes in the control group than in the guided deescalation group. However, these differences did not reach a level of statistical significance and were most pronounced for minimal and minor bleeds, while we observed no relevant reduction in BARC 3-5 bleeding in the guided deescalation group. However, even minor bleeds might have important effects on treatment compliance and healthcare costs. [27] [28] [29] The relative risk reductions observed for bleeding risk in this study are similar to the differences observed in prasugrel versus clopidogrel study groups in the TRITONTIMI trial. 2 Nevertheless, the overall reduction in bleeding risk by deescalation was smaller than expected, which might at least in part be due to the fact that about 40% of patients in the guided deescalation group showed HPR on clopidogrel and continued prasugrel maintenance treatment.
Even though this study uses PFT to back up de escalation in a cohort of patients in which potent platelet inhibition is established and recommended, it should not be considered primarily a PFT study. Nevertheless, our trial needs to be discussed against the background of previous studies using PFT to tailor DAPT. ADAPTDES 15 and large metaanalyses 14 have confirmed the predictive value of PFT for ischaemic and bleeding events after PCI. However, subsequent randomised 
HR (95% CI
Favours control Favours guided de-escalation trials implementing PFT for guidance of antiplatelet therapy failed to show a positive effect of testing on patient outcomes. Yet, the concepts of tailored treatment tested in previous trials substantially differ from the approach of guided deescalation investigated in this study. Earlier trials aimed to test PFTguided escalation rather than deescalation of DAPT focusing pre dominantly 30, 31 or exclusively 32 on lowrisk elective PCI patients. The recent ANTARCTIC trial 33 is the only previous trial using PFT to tailor DAPT in a dedicated acute coronary syndrome cohort. However, there are substantial differences in study design between ANTARCTIC and this study: ANTARCTIC randomly assigned patients with acute coronary syndrome who were aged 75 years or older to receive oral prasugrel 5 mg daily with or without dose or drug adjustment for escalation or deescalation depending on platelet function monitoring. In essence, ANTARCTIC compared the effect of prasugrel 5 mg to a regimen in which lowdose prasugrel was replaced by clopidogrel 75 mg in less than half of patients. This is a limitation of ANTARCTIC, because superiority of low dose prasugrel (5 mg) compared with clopidogrel 75 mg with respect to clinical outcomes has never been confirmed. Hence, TROPICALACS is the only trial designed to test PFT guided deescalation of standard dose prasugrel to clopidogrel in allcomers patients with acute coronary syndrome. Generally, standardised platelet function assays are practical and have already been implemented into clinical routine. 34 From an economic point of view, costs for PFT are marginal, while cost savings when using offpatent clopidogrel instead of potent platelet inhibitors can be substantial. 29 Our study population was characterised by a high proportion (>50%) of highrisk STEMI patients. STEMI patients derived a net clinical benefit from guided DAPT deescalation. This is not contradictory to observations made in TRITONTIMI, 35 where STEMI patients showed the greatest benefit of potent inhibition very early after PCI, a time frame where also in TROPICALACS both groups received uniform prasugrel treatment. One underlying reason for the positive interaction observed for STEMI patients might be related to the fact that this cohort is characterised by less comorbidities and a lower frequency of multivessel disease when compared with NSTEMI patients. 36 In fact, the idea of tailored de escalation in STEMI patients was brought up years ago, 37 based on the results of the STEMI subgroup in TRITON TIMI. 35 Our study tackles this hypothesis and suggests that STEMI patients could be good candidates for DAPT deescalation, whenever this is deemed necessary. In addition, younger patients (≤70 years), constituting 86% of the entire study population, also showed favourable outcomes with guided deescalation. Nevertheless, subgroup analyses should be understood as descriptive and hypothesis generating. Definite answers on what subgroups derive a significant clinical benefit from guided deescalation would require even larger clinical trials powered to show superiority.
We acknowledge limitations related to our clinical trial. The noninferiority margin of 30% chosen for our study can be considered as a potential limitation. However, in posthoc analyses noninferiority for the primary endpoint was even maintained with a smaller noninferiority margin of 10% (p noninferiority =0·0117). This, together with the fact that both ischaemic as well as bleeding event rates if any were numerically lower, but not higher with guided deescalation compared with standard treatment, justifies implementation of guided deescalation as an alternative treatment strategy into clinical practice. Our protocol mandated for choosing prasugrel. Thus, to what extent our findings can be extrapolated to ticagrelor remains unclear. Nevertheless, prasugrel and ticagrelor have very similar P2Y 12 inhibitory effects 38 and a randomised study comparing the two drugs in patients with acute coronary syndrome showed similar efficacy and safety outcomes. 10 This suggests that our findings could indeed apply to patients with acute coronary syndrome treated with ticagrelor. TROPICALACS was planned as an allcomers trial and did not preferentially enrol patients susceptible to bleeding complications, even though they represent potential and excellent candidates for PFT guided de escalation and are more likely to deescalate DAPT post discharge based on large observational registries. 9 However, patients susceptible to bleeding complications were also excluded from the PLATO and TRITONTIMI 38 trials.
1,2 Hence, whether these patients derive a net clinical benefit from potent platelet inhibitors in the first place is unclear. As a consequence, enrolment of patients susceptible to bleeding into a trial using prasugrel in one study arm is probably limited by preferential upfront use of clopidogrel in these patients and the reduced adherence to potent platelet inhibition. Finally, further limitations of our trial are the openlabel design, the exclusion of patients with a history of stroke, and the proportion of patients lost to followup, which was 4% in both study groups.
In conclusion, a guided deescalation of antiplatelet treatment was noninferior to standard treatment with prasugrel in terms of net clinical benefit. A concept of guided deescalation was characterised by a high rate of adherence to treatment and proved feasible in clinical practice. Together, our trial provides important evidence for patients with acute coronary syndrome after successful PCI in whom early deescalation is considered as an alternative strategy.
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Dual antiplatelet therapy guided by platelet function testing
Oral P2Y 12 receptor inhibitors are key for secondary prevention of atherothrombotic events in patients with acute coronary syndromes, in particular those undergoing percutaneous coronary intervention (PCI) 1 . Prasugrel and ticagrelor are more potent than clopidogrel, which is characterised by increased rates of high ontreatment platelet reactivity (HPR), a known marker for recurrent ischaemic events, including stent thrombosis. 2 This characteristic could explain the greater reduction in atherothrombotic events, albeit at the expense of more bleeding, associated with prasugrel and ticagrelor therapy among patients with acute coronary syndromes undergoing PCI. 1 These observations have stimulated research aimed at understanding how to implement platelet function testing (PFT) to guide the selection of P2Y 12 inhibiting therapies. 3 However, previous randomised controlled trials (RCTs) using PFT have failed to show any effect on clinical outcomes and thus PFT is not recommended for routine use. [4] [5] [6] [7] In The Lancet, Dirk Sibbing and colleagues 8 report the results of the TROPICAL-ACS trial, which investigated the safety and efficacy of early de-escalation of antiplatelet treatment from prasugrel to clopidogrel guided by PFT. 2610 patients with acute coronary syndrome undergoing PCI were randomly assigned to standard treatment with prasugrel for 12 months (control group; n=1306) or a de-escalation regimen (1 week prasugrel followed by 1 week of clopidogrel and PFT-guided maintenance therapy with clopidogrel or prasugrel from day 14 after hospital discharge; guided de-escalation group; n=1304). The primary endpoint (a composite of ischaemic and bleeding events at 1 year) was met (7·3% in the de-escalation group vs 9·0% in the control group; p non-inferiority =0·0004; hazard ratio [HR] 0·81 [95% CI 0·62-1·06], p superiority =0·12), supporting the non-inferiority hypothesis of a guided de-escalation strategy compared with standard treatment with prasugrel (control). De-escalation did not result in an increase in ischaemic events (2·5% in the de-escalation group vs 3·2% in the control group; p non-inferiority =0·0115), and there were no differences in the key secondary endpoint of Bleeding Academic Research Consortium criteria type 2 or higher bleeding (4·9% in the deescalation group vs 6·1% in the control group; HR 0·82 [95% CI 0·59-1·13]; p=0·2257). The authors should be commended for this investigation, which is the first to my knowledge to test PFT-guided de-escalation therapy in patients with acute coronary syndrome undergoing PCI and meets its primary endpoint (appendix). [4] [5] [6] [7] [8] Indeed, differences in trial design, patient risk-profiles, and antiplatelet treatment regimens, among other variables, might explain the different outcomes across RCTs (appendix). [4] [5] [6] [7] [8] Additionally, TROPICAL-ACS further expands on the topic of de-escalation, which has yielded conflicting findings in recently reported studies performed without PFT guidance. 9, 10 Based on the non-inferiority trial design, the take-home message of TROPICAL-ACS is that, in patients with acute coronary syndrome undergoing PCI, PFT-guided selection of P2Y 12 inhibiting therapy could represent an alternative approach to a standard strategy of prasugrel use. Although it might be argued that the non-inferiority margin of 30% is broad, a post-hoc analysis showed that the non-inferiority was maintained by applying a margin of 10%. The absence of an increase in ischaemic events, but no reduction in bleeding complications, needs to be viewed in light of the trial strategy. In fact, while the PFT-guided strategy in TROPICAL-ACS helped to prevent ischaemic events by minimising the HPR status, this could have contributed to the absence of differences in bleeding between groups due to the fact that following de-escalation about 40% of patients had HPR and required escalation to prasugrel therapy, reducing the chances to observe a safety See Online for appendix Dr P Marazzi/Science Photo Library benefit. 8 From a practical perspective, a strategy of PFTguided de-escalation therapy might be useful in patients who might not be suitable for prolonged therapy with potent P2Y 12 inhibitors, such as those at increased risk of bleeding or with limited access to extended treatment with the more costly prasugrel. Indeed, bleeding concerns and socioeconomic factors are key contributors to de-escalation therapy in real-world practice. 11 There are some limitations of TROPICAL-ACS. First, although easy-to-use PFT is broadly available, there are a substantial number of HPR patients after de-escalation who then need to escalate therapy. This so-called back and forth management of antiplatelet therapy can be a source of confusion for some patients and might also be challenging to implement if patients cannot easily access centres that conduct PFT. Moreover, multiple factors can contribute to the variability in PFT results and thus defining the HPR status. 3 Strategies that can overcome the above mentioned limitations are needed. To this extent, genetic testing might be of potential value and is currently under investigation. 12 Although prasugrel and ticagrelor achieve similar levels of P2Y 12 inhibition, it might be argued that the study findings cannot be extrapolated to ticagrelor because its off-target effects have been advocated to contribute to its overall benefits.
1 Another consideration to be made is that the study findings cannot be applied to all patients with acute coronary syndromes because elderly individuals, patients with a previous cerebrovascular event, and those with medically managed acute coronary syndrome were excluded.
Despite the diagnostic value of PFT, over the past decade, RCTs have failed to show its role in guiding the choice of antiplatelet therapy. In turn, PFT has struggled to find a space in routine clinical practice. The experience from previous studies led to the design of the TROPICAL-ACS trial, the results of which now provide additional insights on how to use PFT to help select a P2Y 12 inhibitor, thus suggesting a potential resurgence of a nearly abandoned instrument. Future research should build upon TROPICAL-ACS to help to define antiplatelet treatment approaches associated with optimal safety and efficacy performance profiles for the individual patient.
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